Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2024 Earnings Call Transcript

John Bencich: Yes. Good question. So, as part of our discussion with FDA around the open-label trial, they indicated that this study, one, would be needed for both a smoking indication and a vaping indication. But, I think the key piece here is that this trial we’re running now will work for both. So, we will not have to run a separate longer-term exposure trial for a vaping indication, which is why we are allowing both subjects from our smoking trials as well as the vaping study into this new trial.

Ilya Zubkov: Great. Thank you, John.

John Bencich: Yes. Thank you, Ilya.

Operator: Thank you. That brings us to the end of the question-and-answer session. I would like to turn the floor back over to Mr. Bencich, for closing comments.

John Bencich: Thanks, Donna. We’ve made tremendous progress this year and look forward to providing additional updates as we proceed, in particular in the coming weeks as we look to initiate enrollment in the ORCA-OL trial. So, thanks again everyone for joining us today, and for your continued support of Achieve.

Operator: Ladies and gentlemen, this concludes today’s event. You may disconnect your lines and log-off the webcast at this time and enjoy the rest of your day.